HC Wainwright Issues Positive Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – HC Wainwright raised their Q4 2027 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Monday, July 27th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of $0.18 per share for the quarter, up from their previous forecast of $0.16. HC Wainwright currently has a “Buy” rating and a $115.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.08) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm’s revenue was down 86.4% on a year-over-year basis. During the same period last year, the business earned $2.75 earnings per share.

Several other research firms have also weighed in on ARWR. Piper Sandler restated an “overweight” rating and set a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Morgan Stanley raised their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. JPMorgan Chase & Co. boosted their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Chardan Capital upped their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.08.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $85.53 on Tuesday. The firm has a market capitalization of $12.05 billion, a P/E ratio of -39.78 and a beta of 1.26. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41. The firm’s fifty day moving average price is $78.17 and its two-hundred day moving average price is $70.12. Arrowhead Pharmaceuticals has a 1 year low of $15.01 and a 1 year high of $95.49.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $25,000. Optiver Holding B.V. grew its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.